# A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

> **NCT03502707** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 669 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** RSV preF Protein 50 mcg
- **BIOLOGICAL:** RSV preF Protein 150 mcg
- **BIOLOGICAL:** Ad26.RSV.preF 1*10^11 vp
- **BIOLOGICAL:** Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg
- **BIOLOGICAL:** Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg
- **BIOLOGICAL:** Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg
- **BIOLOGICAL:** Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg
- **BIOLOGICAL:** Selected Regimen

## Key facts

- **NCT ID:** NCT03502707
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-06
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-16
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502707, "A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03502707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*